HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuromuscular Blocking Agent Cisatracurium Attenuates Lung Injury by Inhibition of Nicotinic Acetylcholine Receptor-α1.

AbstractBACKGROUND:
Neuromuscular blocking agents (NMBAs) bind the nicotinic acetylcholine receptor α1 (nAChRα1) that also contributes to inflammatory signaling. Thus, the author hypothesized that the use of NMBA mitigates lung injury by improving ventilator synchrony and decreasing inflammatory responses.
METHODS:
Lung injury was induced by intratracheal instillation of hydrogen chloride in rats that were randomized to receive no NMBA with evidence of asynchronous ventilation (noNMBA/aSYNC, n = 10); no NMBA with synchronous ventilation (noNMBA/SYNC, n = 10); cisatracurium (CIS, n = 10); or pancuronium (PAN, n = 10). Mechanical ventilation was set at a tidal volume of 6 ml/kg and positive end-expiratory pressure 8 cm H2O for 3 h. Human lung epithelial, endothelial, and CD14⁺ cells were challenged with mechanical stretch, lipopolysaccharide, lung lavage fluids (bronchoalveolar lavage fluid), or plasma obtained from patients (n = 5) with acute respiratory distress syndrome, in the presence or absence of CIS or small-interfering RNA and small hairpin RNA to attenuate the cell expression of nAChRα1.
RESULTS:
The use of CIS and PAN improved respiratory compliance (7.2 ± 0.7 in noNMBA/aSYNC, 6.6 ± 0.5 in noNMBA/SYNC, 5.9 ± 0.3 in CIS, and 5.8 ± 0.4 cm H2O/l in PAN; P < 0.05), increased PaO2 (140 ± 54, 209 ± 46, 269 ± 31, and 269 ± 54 mmHg, respectively, P < 0.05), and decreased the plasma levels of tumor necrosis factor-α (509 ± 252 in noNMBA, 200 ± 74 in CIS, and 175 ± 84 pg/ml in PAN; P < 0.05) and interleukin-6 (5789 ± 79, 1608 ± 534, and 2290 ± 315 pg/ml, respectively; P < 0.05). The use of CIS and PAN or silencing the receptor nAChRα1 resulted in decreased cytokine release in the human cells in response to a variety of stimuli mentioned earlier.
CONCLUSIONS:
The use of NMBA is lung protective through its antiinflammatory properties by blocking the nAChRα1.
AuthorsVito Fanelli, Yasumasa Morita, Paola Cappello, Mirna Ghazarian, Bina Sugumar, Luisa Delsedime, Jane Batt, V Marco Ranieri, Haibo Zhang, Arthur S Slutsky
JournalAnesthesiology (Anesthesiology) Vol. 124 Issue 1 Pg. 132-40 (Jan 2016) ISSN: 1528-1175 [Electronic] United States
PMID26540149 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Neuromuscular Blocking Agents
  • Receptors, Nicotinic
  • Atracurium
  • cisatracurium
Topics
  • Analysis of Variance
  • Animals
  • Atracurium (analogs & derivatives, pharmacology)
  • Disease Models, Animal
  • Inflammation (complications, prevention & control)
  • Lung Injury (complications, prevention & control)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuromuscular Blocking Agents (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Nicotinic (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: